Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats

Addiction Biology

Volumn 8, Issue 2, 2003, Pages 159-166

  González, Sara ^a   Schmid, Patricia C ^b   Fernández Ruiz, Javier ^a   Krebsbach, Randy ^b   Schmid, Harald H O ^b   Ramos, José A ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; NALOXONE; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG EFFECT; DRUG RECEPTOR BINDING; MALE; MORPHINE ADDICTION; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; REINFORCEMENT;

ANALGESICS; ANIMALS; ARACHIDONIC ACIDS; BINDING SITES; CEREBRAL CORTEX; CORPUS STRIATUM; DRUG ADMINISTRATION SCHEDULE; ENDOCANNABINOIDS; INJECTIONS, INTRAVENOUS; MALE; MESENCEPHALON; MORPHINE; MORPHINE DEPENDENCE; MORPHOLINES; NAPHTHALENES; NARCOTICS; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; REINFORCEMENT (PSYCHOLOGY); SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 0037810418     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/1355621031000117383     Document Type: Article

References (41)

1. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998;21:521-8.
2. Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K. The neurobiology of cannabinoid analgesia. Life Sci 1999;65:665-73.
3. Fernández-Ruiz J, Berrendero F, Hernández ML, Ramos JA. The endogenous cannabinoid system and brain development. Trends Neurosci 2000;23:14-20.
4. Fernández-Ruiz JJ, Lastres-Becker I, Cabranes A, González S, Ramos JA. Endocannabinoids and basal ganglia functionality. Prostaglandins, Leukot, Essent Fatty Acids 2002;66:257-67.
5. Amone M, Maruani J, Chaperon F, et al. Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Pyschopharmacology 1997;132:104-6.
6. 1 receptor knockout mice. Science 1999;283:401-4.
7. Manzanares J, Corchero J, Romero J, Fernández-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharm Sci 1999;20:287-94.
8. 1 receptor knockout mice. Eur J Pharmacol 1999;383:R1-2.
9. Hungund BL, Basavarajappa BS. Are anandamide and cannabinoid receptors involved in ethanol tolerance? A review of the evidence. Alcohol Alcohol 2000;35:126-33.
10. Gardner EL, Vorel SR. Cannabinoid transmission and reward-related events. Neurobiol Dis 1998;5:502-33.
11. Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W. Self-administration of the cannabinoid receptor agonist WIN55,212-2 in drug-naive mice. Neuroscience 1998;85:327-30.
12. Tanda G, Munzar P, Goldberg SR. Self-administration behaviour is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nature Neurosci 2000;3:1073-4.
13. Lukas SE, Sholar M, Kouri E, Fukuzako H, Mendelson JH. Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. Pharmacol Biochem Behav 1994;48:715-21.
14. 1 receptor agonist. Eur J Pharmacol 1999;370:233-40.
15. Vela G, Ruiz-Gayo M, Fuentes JA. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 1995;34:665-8.
16. 1) receptors in the establishment of place conditioning in rats. Psychopharmacology 1998;135:324-32.
17. 1 cannabinoid receptor agonist WIN55,212-2 decreases intravenous cocaine self-administration in rats. Behav Brain Res 1999;104:141-6.
18. Arnold JC, Topple AN, Hunt GE, McGregor IS. Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP55,940 on behavioural sensitization to cocaine. Eur J Pharmacol 1998;354:9-16.
19. Colombo G, Agabio R, Fa M, et al. Reduction of voluntary ethanol intake in ethanol preferring SP rats by the cannabinoid antagonist SR141716. Alcohol Alcohol 1998;33:126-30.
20. Rubino T, Tizzoni L, Vigano D, Massi P, Parolaro D. Modulation of rat brain cannabinoid receptors after chronic morphine treatment. Neuroreport 1997;8:3219-23.
21. 1 receptor binding and mRNA levels. Drug Alcohol Depend 2002;66:77-84.
22. 35S]GTPγS binding in morphine-dependent mice. Drug Alcohol Depend 1998;50:241-9.
23. Sim-Selley LJ, Selley DE, Vogt LJ, Childers SR, Martin TJ. Chronic heroin self-administration desensitizes μ opioid receptor-activated G-proteins in specific regions of rat brain. J Neurosci 2000;20:4555-62.
24. Basavarajappa BS, Hungund BL. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells. J Neurochem 1999;72:522-8.
25. Basavarajappa BS, Saito M, Cooper TB, Hungund BL. Stimulation of cannabinoid receptor agonist 2-arachidonoylglycerol by chronic ethanol and its modulation by specific neuromodulators in cerebellar granule neurons. Biochim Biophys Acta 2000;1535:78-86.
26. Koob GF. Neurobiology of addiction. Toward the development of new therapies. Ann NY Acad Sci 2000;909:170-85.
27. Shippenberg TS, Elmer GI. The neurobiology of opiate reinforcement. Crit Rev Neurobiol 1998;12:267-303.
28. Fuentealba JA, Forray MI, Gysling K. Chronic morphine treatment and withdrawal increase extracellular levels of norepinephrine in the rat bed nucleus of stria terminalis. J Neurochem 2000;75:741-8.
29. Sugiura T, Yoshinaga N, Waku K. Rapid generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in rat brain after decapitation. Neurosci Lett 2001;297:175-8.
30. Schmid PC, Schwartz KD, Smith CN, Krebsbach RJ, Berdyshev EV, Schmid HHO. A sensitive endocannabinoid assay. The simultaneous analysis of N-acylethanolamines and 2-monoacylglycerols. Chem Phys Lipids 2000;104:185-91.
31. Folch J, Lees M, Sloane Stanley GH. A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-509.
32. Schmid PC, Kuwae T, Krebsbach RJ, Schmid HHO. Anandamide and other N-acylethanolamines in mouse peritoneal macrophages. Chem Phys Lipids 1997;87:103-10.
33. 3H]-CP-55,940 binding to the cannabinoid receptor. Du Pont Biotech Update 1991;6:21-7.
34. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1995;47:848-54.
35. Bisogno T, Berrendero F, Ambrosino G, et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Comm 1999;256:377-80.
36. 1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 1998;9:3397-402.
37. 1 receptor antagonist, influences morphine withdrawal syndrome. Life Sci 2000;66:2213-19.
38. 1 antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 2001;132:1809-16.
39. Vigano D, Fezza F, Cascio MG, et al. Reduction of endocannabinoid contents in several brain regions after chronic morphine treatment in rats. Symposium on the Cannabinoids, Burlington Vermont International Cannabinoid Research Society, 2001.
40. Way EL, Loh HH. Responsivity to naloxone during morphine dependence. Ann NY Acad Sci 1976;281:252-61.
41. Christie MJ, Williams JT, Osborne PB, Bellchambers CE. Where is the locus in opioid withdrawal? Trends Pharmacol Sci 1997;18:134-40.